HALO logo
halo search icon
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc.
RNAZ · NAS

TransCode Therapeutics, Inc.

US$6.12

Price Arrow0.005 (0.082%)
21/05/2026 03:42:06 PM
All-CompaniesBig CandleHALO AllNear Support
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

TransCode Therapeutics, Inc. Overview

RNAZ Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About RNAZ

icon

Website

TransCode Therapeutics, Inc.

icon

Telephone

1.857.837.3099

icon

Address

Suite 2382, 6 Liberty Square, Boston, MA 02109

Description

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

RNAZ Price Chart

Key Stats

Market Cap

US$5.81M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 5.56 - 20.99

Trade Value (12mth)

US$350,149.00

1 week

-7.42%

1 month

-28.93%

YTD

-17.43%

1 year

-19.82%

All time high

5174400.00

Key Fundamentals

EPS 3 yr Growth

-100.00%

EBITDA Margin

0.00%

Operating Cashflow

-$20m

Free Cash Flow Return

-26.00%

ROIC

-46.30%

Interest Coverage

NaN

Quick Ratio

6.30

Other Data

Shares Outstanding (Fully Diluted)

1m

HALO Sector

Healthcare

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

RNAZ Announcements

Latest Announcements

DateAnnouncements
16 May 26
01 May 26
01 May 26
01 May 26
22 April 26

RNAZ Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-95,731.94-1,317.38-52.59locklocklock
EPS (Fully Diluted)
$locklocklocklock-95,731.94-1,317.38-52.59locklocklock
Growth
%locklocklocklock90.498.696locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of TransCode Therapeutics, Inc. (RNAZ:NAS)?
Halo FAQ
The current share price of TransCode Therapeutics, Inc. (RNAZ:NAS) is USD$6.12.
What is the 52-week high share price for TransCode Therapeutics, Inc. (RNAZ:NAS)?
Halo FAQ
The 52-week high share price for TransCode Therapeutics, Inc. (RNAZ:NAS) is USD$20.99.
What is the 52-week low share price for TransCode Therapeutics, Inc. (RNAZ:NAS)?
Halo FAQ
The 52-week low share price for TransCode Therapeutics, Inc. (RNAZ:NAS) is USD$5.56.
What is the dividend yield for TransCode Therapeutics, Inc. (RNAZ:NAS)?
Halo FAQ
TransCode Therapeutics, Inc. (RNAZ:NAS) does not pay a dividend.
What was TransCode Therapeutics, Inc. (RNAZ:NAS) last dividend payment?
Halo FAQ
TransCode Therapeutics, Inc. (RNAZ:NAS) does not pay a dividend.
What is the franking level for TransCode Therapeutics, Inc. (RNAZ:NAS)?
Halo FAQ
TransCode Therapeutics, Inc. (RNAZ:NAS) has a franking level of 0.00%.
In which sector is TransCode Therapeutics, Inc. (RNAZ:NAS) classified?
Halo FAQ
TransCode Therapeutics, Inc. (RNAZ:NAS) is classified in the Healthcare.

See beyond the curve.

One solution for research, investing and portfolio management.